Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05533775 | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma(iMATRIX GLO) | recruiting | Phase 1 / Phase 2 | 65 | Hoffmann-La RocheINDUSTRY | 13 | Sep 3, 2026 | clinicaltrials |
| NCT05583617 | A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma(PLYCOM) | recruiting | Phase 1 / Phase 2 | 200 | Hoffmann-La RocheINDUSTRY |
| 6 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT06822972 | HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM | recruiting | Phase 2 | 27 | Duke UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04803201 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 170 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04930653 | Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | recruiting | Phase 2 | 34 | City of Hope Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04546399 | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | recruiting | Phase 2 | 461 | National Cancer Institute (NCI)NIH | 4 | Sep 1, 2026 | clinicaltrials |
| NCT06561347 | Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM(ZEBRA) | recruiting | Phase 2 | 65 | Massachusetts General HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07029737 | A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain(SOUND-MCL) | recruiting | Phase 2 | 55 | AstraZenecaINDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07432022 | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05272826 | Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients(BOREALIS) | recruiting | Phase 2 | 75 | Canadian Myeloma Research GroupOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05886036 | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT06108232 | Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma | recruiting | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06138275 | Elranatamab in R/R Multiple Myeloma | recruiting | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 62 | Natalie CallanderOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07551583 | Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL | recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07734038 | Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | recruiting | Phase 2 | 155 | Kerry RogersOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05344833 | Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma(HEME-18) | recruiting | Phase 2 | 50 | University of Illinois at ChicagoOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06648889 | Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 28 | Goethe UniversityOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06687772 | CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant(CNS-PHLAT) | recruiting | Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06784726 | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | recruiting | Phase 2 | 27 | University of WashingtonOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07123454 | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma(Lumi-NHL) | recruiting | Phase 1 / Phase 2 | 91 | AstraZenecaINDUSTRY | 8 | Aug 28, 2026 | clinicaltrials |
| NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | City of Hope Medical CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | recruiting | Phase 1 / Phase 2 | 150 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07589634 | A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma(TRI Pro) | recruiting | Phase 2 | 230 | Janssen Research & Development, LLCINDUSTRY | 4 | Aug 28, 2026 | clinicaltrials |
| NCT05623982 | A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06066203 | A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06442475 | Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma | recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07681596 | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 101 | AstraZenecaINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT06940297 | Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 2 | 44 | Mayo ClinicOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 70 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05826535 | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 270 | Lyell Immunopharma, Inc.INDUSTRY | 2 | Aug 25, 2026 | clinicaltrials |
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 38 | Yazeed SawalhaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06594939 | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 31 | Medical College of WisconsinOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) | recruiting | Phase 2 | 200 | GlaxoSmithKlineINDUSTRY | 8 | Aug 25, 2026 | clinicaltrials |
| NCT06087653 | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 24 | Starton Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07220616 | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 420 | Daiichi SankyoINDUSTRY | 4 | Aug 24, 2026 | clinicaltrials |
| NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | recruiting | Phase 1 / Phase 2 | 146 | BeiGeneINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04792502 | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | recruiting | Phase 2 | 52 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06495723 | Polyspecific Antibodies in Lymphoproliferative T-cell Disorders(PALT1) | recruiting | Phase 1 / Phase 2 | 54 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT07021989 | ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 | 38 | Michael Spinner, MDOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07275216 | Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment | recruiting | Phase 2 | 23 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT05082519 | Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL(IDEAL2) | recruiting | Phase 2 | 240 | Etan OrgelOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 37 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT05977673 | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy(FIL_Tisle-HL) | recruiting | Phase 2 | 28 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials